DNSP 11 5mg

• Sequence: PPEAPAEDRSL-NH2
• Molecular Formula: C50H81N15O18 • xC2HF3O2
• Molecular Weight: 1180.27 g/mol
• Peptide Purity: Greater than 98%
• Additional Information: No TFA Salt

Parkinson's disease (PD) is the second most common severe neurodegenerative disorder, often characterized by the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Current treatments only manage symptoms and do not offer neuroprotection or neurorestorative.

Neurotrophic factors like glial cell line-derived neurotrophic factor (GDNF) have shown promise in animal models for the protection and restoration of damaged dopamine neurons. However, the delivery and synthesis of such factors present challenges.

DNSP-11, a short 11-amino acid amidated peptide derived from the proGDNF domain, has been studied for its neurobiological effects. In animal models, a single injection of DNSP-11 into the substantia nigra led to increased resting dopamine levels and its metabolites 28 days post-injection. Furthermore, DNSP-11 demonstrated significant behavioural improvements in severe PD models in rats.

In vitro studies indicate that DNSP-11 supports the survival of primary mesencephalic neurons and neurite outgrowth. It also shows protective effects against cell death induced by various agents, as evidenced by reduced levels of caspase-3 activity and TUNEL-positive cells.

In summary, DNSP-11 may target similar molecular mechanisms as other compounds under investigation for PD. These findings suggest that DNSP-11 possesses neurotrophic-like properties, making it a subject of interest for further research in the context of neurodegenerative disorders.